Powering Amyloid Beta Degrading Enzymes: A Possible Therapy for Alzheimer's Disease.
Neurochem Res
; 44(6): 1289-1296, 2019 Jun.
Article
em En
| MEDLINE
| ID: mdl-30806879
ABSTRACT
The accumulation of amyloid beta (Aß) in the brain is believed to play a central role in the development and progression of Alzheimer's disease. Revisions to the amyloid cascade hypothesis now acknowledge the dynamic equilibrium in which Aß exists and the importance of enzymes involved in the production and breakdown of Aß in maintaining healthy Aß levels. However, while a wealth of pharmacological and immunological therapies are being generated to inhibit the Aß-producing enzymes, ß-site APP cleavage enzyme 1 and γ-secretase, the therapeutic potential of stimulating Aß-degrading enzymes such as neprilysin, endothelin-converting enzyme-1 and insulin-degrading enzyme remains relatively unexplored. Recent evidence indicates that increasing Aß degradation as opposed to inhibiting synthesis is a more effective strategy to prevent Aß build-up. Therefore Aß degrading enzymes have become valuable targets of therapy. In this review, we discuss the pathway of Aß synthesis and clearance along with the opportunities they present for therapeutic intervention, the benefits of increasing the expression/activity of Aß-degrading enzymes, and the untapped therapeutic potential of enzyme activation.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neprilisina
/
Peptídeos beta-Amiloides
/
Ativadores de Enzimas
/
Proteólise
/
Enzimas Conversoras de Endotelina
/
Insulisina
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article